SEC Form 4 · accession 0001193125-26-335373
MBX Biosciences, Inc. · MBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Salomon Azoulay
Officer — Chief Medical Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 5, 2026 · 4:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001776111
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 4, 2026 | S | 370 | $65.77 | D | 14,399 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
- F2The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
Remarks
Exhibit 24 - Power of Attorney